Three lactating Holstein cows (634 to 698 kg) were dosed, respectively, with 65.6 mg (44.5 mCi/ mg), 131.2 mg (20.1 mCi/mg), or 8.4 mg (141.3 mCi/ mg) of [ 14 C]nitrofurazone by intramammary, intrauterine, or topical ocular administration. Intramammary and intrauterine treatments were single doses; ocular treatment was daily for 4 consecutive d (2.1 mg/d). Cows were slaughtered after 72-h withdrawal periods. Excreta and milk were quantitatively collected from each cow after dosing. Seventy-two hours after treatment, urine, feces, and milk contained 62.9, 17.6, and 2.3%, respectively, of the radiocarbon administered intramammarily to the cow. Radioactive residues in milk collected from the dosed quarter were 150 ppb (nitrofurazone equivalents) and were 39 ppb in milk collected from the undosed quarters at 12 h after dosing. Urine, feces, and milk from the cow that received the intrauterine dose contained 12.24, 5.17, and 0.13% of the administered dose, respectively, at 72 h after treatment. Concentrations of total radioactive residues in milk were 9.3 ppb at 12 h after dosing. For the cow that was dosed ocularly, the cumulative excretion of radiocarbon in urine, feces, and milk was 17.6, 28.5, and 0.5% of the dose, respectively. Milk residues from the cow that was dosed ocularly were never >1 ppb of nitrofurazone equivalents. Livers and kidneys contained the greatest amounts of residues relative to other edible tissues. Parent nitrofurazone was not suitable as a marker compound to determine total residues in milk using HPLC analysis. Radioactive residues were available systemically and were excreted in milk after intramammary, intrauterine, or ocular application of [ 14 C]nitrofurazone. Illegal residues in milk and edible tissues would result from the administration of nitrofurazone to lactating cows. ( Key words: nitrofurazone, absorption, lactation, residue)
INTRODUCTION
Nitrofurazone ( NFZ; 5-nitro-2-furaldehyde semicarbazone) is a broad-spectrum antibiotic that has historically been used in a variety of livestock species for therapeutic purposes and to promote growth ( 7 ) . In the US, NFZ was first approved for use in farm animals in 1948 ( 1 ) , but, in 1971, the US FDA proposed withdrawal of the approval because of evidence that NFZ caused tumors in laboratory animals ( 1 ) . Nitrofurazone was not shown to be safe under the conditions for which the original application had been approved ( 2 ) . The major concern with the use of NFZ in food animals is its potential to promote tumor formation ( 1 ) or to act as a secondary carcinogen ( 5 ) . The carcinogenicity of NFZ in humans has been questioned ( 5 ) .
In the US, no tolerance for NFZ has been established, and internationally no maximum residue level has been set ( 3 ) ; therefore, residues of parent NFZ and its metabolites are not permitted in edible tissues or in milk from food animals. Tolerances and maximum residue limits for NFZ were not established because of a paucity of data regarding metabolism and total residue data in target species (1, 3) .
The off-label use of NFZ for the treatment of mammary or uterine infection has been of public health concern to the US FDA because NFZ was formerly labeled for such use ( 2 ) and because NFZ is currently marketed as a topical treatment for keratoconjunctivitis (pinkeye) in animals used for food. The disposition and total residue profile of NFZ after these routes of administration are unknown but are of pub- lic health concern if parent NFZ or its metabolites are present in milk or edible tissues of treated animals.
The use of radiolabeled test drugs allows the disposition and total residue profile of a drug to be determined (11) . Nonradioactive drugs may be used, but only with difficulty. Specific assays for the parent drug (unmetabolized drug) and its metabolites must be developed and validated for each tissue of interest. Radiolabeled drugs are advantageous because the total radioactive residues (parent drug plus metabolites) can be measured easily and quickly, regardless of the matrix. An additional benefit of using radiolabeled material for residue studies is that the relationship between total radioactive residues and a marker compound can be established (11) . The marker compound can then be used to estimate total drug-related residues in tissues from animals treated with the nonradioactive form of the drug.
The primary objective of this study was to determine the distribution of radioactive residues after intramammary ( IM) , intrauterine ( IU) , or topical ocular ( TO) application of [ 14 C]NFZ to lactating dairy cows. A second objective was to measure the concentrations of parent NFZ in milk samples after IM or IU administration of [ 14 C]NFZ to determine whether it would be a suitable marker compound for use in residue depletion studies. Figure 1 ] was synthesized by Dupont-NEN (Boston, MA) to a specific activity of 141.3 mCi/mg. Radiochemical purification of [ 14 C]NFZ was performed prior to the dosing of each cow and was accomplished using tandem 0.8-× 10-cm C-18 Nova-Pak columns (Waters, Millford, MA) in radial compression modules. An isocratic solvent system consisting of 75% 0.001 M phosphate buffer (pH 7.0) and 25% methanol was used to elute NFZ. Solvent flow ( 2 ml/min) was controlled with a pump and controller (model 600E; Waters), and NFZ was detected at 254 nm using a UV detector (model 440; Waters). Under these conditions, [ 14 C]NFZ eluted at 9.9 min. Alternatively, an isocratic system consisting of 70% 0.001 M phosphate buffer (pH 7.0) and 30% methanol was utilized with the same instrumentation so that the retention time of NFZ was decreased; under those conditions, NFZ eluted at 5.5 min.
MATERIALS AND METHODS

Test Article and Dose Formulation
Radiochemical purity was assessed using two chromatographic systems. The first consisted of a 250-× 4.6-mm C-18 Symmetry column ( 5 mm; Waters) eluted isocratically with 70% 0.001 M phosphate buffer (pH 7.0) and 30% methanol (flow rate, 1.5 ml/min). The second system consisted of a C-18 Symmetry column eluted with a gradient starting at 95% 0.001 M phosphate buffer (pH 7.0) and 5% methanol; the gradient ended at 0% buffer after 15 min (flow rate, 1.5 ml/min). Eluate was collected into scintillation vials over the duration of each chromatographic run, and the percentage of the injected radioactivity associated with the [ 14 C]NFZ peak was determined. Radiochemical purity of the [ 14 C]NFZ administered to each cow was >99%.
All doses were formulated in polyethylene glycol 400 ( PEG 400) after adjusting the specific activity of the [ 14 C]NFZ with nonradioactive material. [ 14 C]Nitrofurazone administered by IM infusion or IU administration was diluted to specific activities of 44.5 and 20.1 mCi/mg, respectively, by dissolving purified [ 14 C]NFZ in methanol and then adding an appropriate amount of nonradioactive NFZ (Aldrich, Milwaukee, WI). Solutions were mixed and evaporated to dryness; the [ 14 C]NFZ of appropriate specific activity was then formulated in PEG 400. Radioactivity per unit weight of the resulting formulations was determined by placing known masses of the formulated material in volumetric flasks, diluting with methanol, and then measuring the radioactivity per unit volume. [ 14 C]Nitrofurazone used for TO administration was formulated in PEG 400, but its specific activity (141.3 mCi/mg) was not reduced by dilution with nonradioactive NFZ.
Cows
Three healthy, nonmastitic, lactating Holstein dairy cows (cows 1501, 1617, and 1621; 634 to 698 kg) were purchased from the research herd of the North Dakota State University Dairy. Cows were selected based on health, production history, gentleness, and size. Each cow was in either fourth or fifth parity and was 1 to 6 mo into the lactation cycle when delivered to the barn facilities of the Biosciences Research Lab (Fargo, ND). Mean daily milk production during the 5-d period prior to dosing was 27.9, 21.3, and 17.0 kg, respectively, for cows 1501, 1617, and 1621. Cow 1621 was pregnant ( d 62 of her fifth pregnancy when delivered to the barn); the other two cows were not pregnant. Each cow was given ad libitum access to alfalfa or to a mixture of timothy and alfalfa hay plus corn silage; at milking, the cows were provided approximately 2.3 kg of a grain concentrate. Each cow was delivered to the barn facilities at least 1 wk prior to dosing.
On each full day of the adaptation period (the period between the delivery of the cow to the research barn and dosing), each eye of cow 1621 was treated with 100 to 200 ml of PEG 400. Pretreatment with this vehicle during the adaptation period served three purposes. First, treatment allowed the cow to become accustomed to the manipulation of her head; second, treatment gave the researcher experience in the delivery of a liquid dose to the eye of a cow; and third, treatment verified that PEG 400 would not irritate the eye after repeated administrations.
Dose Administration and Sample Collection
Cow 1501 was given a single IM infusion (30 ml) containing 65.6 mg (44.5 mCi/mg) of [ 14 C]NFZ immediately after the morning milking on d 1 of the study. The [ 14 C]NFZ was infused through the teat canal into a single randomly selected quarter using a syringe equipped with a blunt-tipped delivery tube. The remaining quarters were not treated. Blood was collected into heparinized tubes from an indwelling jugular catheter at 1, 3, 6, 12, 24, 36, 48, 60 , and 72 h after dosing. The cow was milked at approximately 12-h intervals for a 72-h period using a portable milking machine. Milk from the quarter dosed with [ 14 C]NFZ was collected separately from milk secreted from the untreated quarters. The total outputs of urine and feces were collected by personnel assigned to watch the cow in consecutive 8-h shifts for the duration of the study. The micturition reflex was induced for urine collection to ensure that radioactivity would not be lost if the cow urinated unexpectedly. Urine, milk, and feces were thoroughly mixed individually before several 500-g subsamples of each were removed, labeled, and frozen until analysis. Cow 1501 was slaughtered (described subsequently) at 72 h after dosing.
A single dose of [ 14 C]NFZ (131.2 mg; 20.1 mCi/mg) that was dissolved in 30 ml of PEG 400 was administered to cow 1617 by IU flooding. Intrauterine flooding was accomplished by inserting an AI catheter through the cervix into the uterus. The [ 14 C]NFZ solution was then displaced into the uterus, and the catheter was removed. Within minutes of dosing, an orange vaginal discharge (indicative of NFZ) was noted. An immediate effort was made to collect all of the discharge and to quantify the amount of radioactive residue present in the discharge. Most of the vaginal discharge was eliminated within 6 h of dosing. Bedding material (wood shavings) contaminated by the vaginal discharge was collected and exhaustively extracted with methanol; the extract was then analyzed by liquid scintillation counting ( LSC) . Combustion analysis of the extracted wood shavings indicated that they contained only trace amounts of radioactive residue after methanol extraction. The radioactive residue eliminated in the vaginal discharge accounted for 72.0% of the dosed radiocarbon. Therefore, a retained dose (total radioactive dose minus the radioactive residue present in the vaginal discharge) was used to calculate the percentage recovery of radioactive residues in milk, urine, feces, and tissues for cow 1617. Blood, milk, urine, and feces were collected for a 72-h period following dosing as was described for cow 1501. Cow 1617 was slaughtered after a 72-h withdrawal period. . Immediately prior to dosing, cow 1621 was milked and tied so that her head was immobilized. Blood was then collected from an indwelling jugular catheter. Dosing was accomplished by applying approximately one-half of the [ 14 C]NFZ solution contained in the syringe to the surface of each eye. A 51-× 61-cm stainless steel tray was held approximately 45 cm beneath the head of the cow so that lacrimal secretions that fell from the eyes could be collected. The tray was held in place until the last visible lacrimation had fallen (about 5 min after the last eye had been dosed). The cow was dosed at 0, 24, 48, and 72 h of the study; dosing was uneventful. Radioactive materials remaining in the syringe and in the collection tray were quantified, and the dose remaining on the eye was calculated. The mean daily dose of [ 14 C]NFZ was 2.1 mg/d (297 mCi). Individual doses ranged from 1.74 (246 mCi) to 2.53 mg (357 mCi), and the cumulative dose was 8.4 mg (1.188 mCi).
Blood was collected immediately prior to the initial dose and at 1, 3, 6, 12, 24, 48, and 72 h relative to the initial dose. Blood samples collected at 24, 48, and 72 h were collected immediately prior to the second, third, and fourth dosing, respectively. Blood samples were also collected at 96, 120, and 144 h after the initial [ 14 C]NFZ dose (24, 48, and 72 h after the final [ 14 C]NFZ dose). Milk, urine, and feces were collected as described for cow 1501. Cow 1621 was slaughtered 72 h after receiving the final dose (144 h after receiving the initial dose).
Approximately 5 min prior to slaughter, each cow was infused with heparin sulfate (330 U/kg of BW). Cows were stunned using a captive bolt stun gun, hung on a rail, and exsanguinated. Blood was collected into a large basin during exsanguination and then weighed; a subsample was removed. The gall bladder, large intestine, small intestine, stomach complex (rumen, reticulum, omasum, and abomasum), skin, adipose tissue, bone, skeletal muscle, lung, heart, spleen, liver, kidney, mammary tissue (dosed and undosed quarters were separated for cow 1501), uterus, and the remainder of the carcass were collected and weighed. For cow 1621, the head, brain, eyes, amniotic fluid, uterus, and fetus were removed and analyzed separately from the remainder of the carcass. Because of the nature of the TO dose, the halter and lead rope were also retained and assayed (cow 1621 only). Large fractions, such as the gastrointestinal tract and carcass, were ground using an industrial meat grinder and mixed; subsamples were removed and frozen (-15°C ) until further processing. Representative samples of muscle, adipose tissue, skin, bone (rib), blood, lung, liver, and mammary tissue were collected and frozen (-15°C ) until further processing.
Analysis of Radioactive Residues
Tissue fractions were ground in an industrial meat grinder and mixed thoroughly; subsamples were then frozen (-15°C). The coarsely ground tissues were homogenized on solid CO 2 (dry ice) using a Waring blender (Waring Corp., Winsted, CT). Samples of bone and skin were cut into small pieces and ground with solid CO 2 . Finely ground tissues were placed in a freezer at -15°C, and the solid CO 2 was allowed to sublimate. Sample containers were then closed and frozen at -15°C until analysis. Quadruplicate or pentaplicate samples of each tissue (0.5 g; 0.15-g samples for fatty tissues) were weighed into combustion boats and capped with cellulose wicks. Samples were combusted using an oxidizer (model 306; Packard Instrument Co., Downers Grove, IL), and radiocarbon content was determined by LSC (10-min counts; model 1600; Packard Instrument Co., Downers Grove, IL).
Urine ( 1 g ) and milk samples (0.5 g for cows 1501 and 1617 and 1 g for cow 1621 because of the small NFZ dose) were weighed into scintillation vials (in quadruplicate or pentaplicate), and 10-to 15-ml of scintillation fluid (ICN Biomedical Inc., Costa Mesa, CA) were added to each sample. Samples were counted for 20 min on a liquid scintillation counter (Beckman Instruments, Fullerton, CA).
Fecal samples were prepared using a homogenization procedure similar to that described for tissues. Blood radioactivity was measured by combustion analysis as described for the feces except that the heparinized blood (0.5 g ) was placed directly into combustion boats.
Metal parts were removed from the halter and lead rope used on cow 1621 and were soaked in methanol. The methanol was placed in volumetric flasks and diluted to volume. Radioactivity in the methanol extracts was determined by counting pentaplicate 1-ml aliquots by LSC. The remaining portion of the halter was weighed, cut into small pieces, and digested in preparation for LSC in 6 M HCl at 50°C. The digested halter was transferred to a 2-L volumetric flask and diluted to volume with water. Two 15-ml aliquots were diluted to 1 L with methanol, and pentaplicate samples ( 2 ml) were removed for LSC.
Attempts to dissolve the lead rope in 6 M HCl were unsuccessful. Therefore, the lead rope was melted in a glass beaker using a lab hot plate. The molten rope was stirred, and strings of molten rope were removed and allowed to solidify. The total mass of the solidified strings and rope was determined, and the strings were crushed with a mallet. Radioactive residues in the crushed material were determined by combustion analysis.
Analysis of Parent NFZ in Milk
Parent NFZ was measured in milk samples from cows that received the IM or IU dose to determine whether NFZ would be a suitable marker compound for use in regulatory assays. The assay was based on the extraction of NFZ under acidic conditions, purification using XAD-2 resin, analysis by HPLC, and quantification of NFZ eluting from the column by radiochemical methods.
Milk samples (30 ml) were obtained for the periods 0 to 12 h for the cow that received the IU treatment; 0 to 12 h and 12 to 24 h from the undosed quarters of the cow that received the IM treatment; and 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h from the dosed quarter of the cow that received the IM treatment. Samples were augmented with 30 mg of nonradioactive NFZ to serve as a carrier for [ 14 C]NFZ (0.3 ml of a methanol solution) and then centrifuged at 1500 × g for 1 h at 4°C. The purpose of the carrier NFZ was to allow the easy detection of NFZ by UV detection; the carrier did not affect quantification of NFZ because radiochemical methods were used. The cream layer was removed and dissolved in 5 ml of methanol; 0.5-ml aliquots were assayed for radiocarbon content by LSC. For each milk sample, the serum layer was transferred to a glass centrifuge tube (250 ml), and 3 ml of 2.5N HCl and 120 ml of ethyl acetate were added. The mixture was stirred for 30 min and centrifuged for 15 min at 2100 × g. The ethyl acetate was removed, and the aqueous layer was extracted two more times, each with 75 ml of ethyl acetate. Ethyl acetate layers were combined and reduced in volume to 200 ml on a rotary evaporator. Aliquots of the aqueous phase and ethyl acetate extract were analyzed for radiocarbon content by LSC.
The ethyl acetate fraction was evaporated to dryness, the residue was dissolved in 15 ml of water, and the aqueous residue was applied to 12 g of XAD-2 resin. The XAD-2 resin, contained in a disposable 20-ml syringe body, had been previously washed with 20 ml of methanol followed by 40 ml of water. The column eluate was collected and diluted to 15.0 ml; radioactivity was quantified by LSC using 1-ml aliquots. The XAD-2 column was then washed with 10 ml of water followed by 40 ml of methanol. The water and methanol fractions were collected, and radiocarbon content was determined by assaying 0.5-and 1.0-ml aliquots, respectively. The radioactivity remaining on the XAD-2 was determined by LSC after approximately 1 g of XAD-2 packing was removed and suspended in scintillation fluid.
The methanol eluate was evaporated to dryness, and the residue was dissolved in 1 ml of 1 mM phosphate buffer (pH 7.0). Three hundred microliters of the reconstituted extract were injected onto a HPLC system consisting of a pump (model 600E; Waters) and detector (254 nm; Model 440; Waters) via an injector (model 7125; Rheodyne, Inc., Cotati, CA). A Waters C-18 Nova-Pak column was eluted with 75% 1 mM phosphate buffer (pH 7.0) and 25% methanol at a flow rate of 2 ml/min. The mobile phase eluting from the column prior to NFZ was collected (polar fraction) and diluted to 20 ml for each analysis. The NFZ peak was easily identified because of its retention time and because nonradioactive NFZ had been added to the sample. The peak was collected into a scintillation vial for LSC. The fraction eluting after NFZ (the nonpolar fraction) was also collected, and the radioactivity present in that fraction and in the polar fraction was determined by LSC.
RESULTS
Total Residues in Blood, Milk, Urine, and Feces
Total radioactive residues in whole blood are shown in Table 1 . Concentrations of radioactive residues in blood were greatest in the 1-h sample for cows treated by IU or TO application and in the 3-h sample for the cow dosed by IM administration. In the cow that received the TO treatment, radioactive residues in blood decreased progressively with sampling time until the cow was dosed again. Blood radioactivity increased after each dose because the blood samples taken at 48, 72, and 96 h (24 h after the second, third, and fourth dose, respectively) had progressively greater concentrations of radioactive residues.
Concentrations of radioactive residues (expressed as NFZ equivalents) secreted in milk are shown in Table 2 . Total radioactive residues were the greatest in milk secreted from the dosed quarter of the cow treated by IM infusion; 12 h after dosing, this milk contained 150 ppb of NFZ equivalents. After 72 h, total radioactive residues had fallen to 4 ppb of NFZ equivalents in milk from the dosed quarter. Radio- 4 Nitrofurazone equivalents. 5 Percentage of the administered radioactive material secreted in milk during the indicated period. Data are expressed as percentages of the retained dose for the cow treated by intrauterine infusion. 6 Not determined. active residues in milk from the undosed quarters were the greatest at 12 h after dosing (39 ppb) and fell to 2 ppb in milk collected 72 h after dosing. Although the cow was dosed via the mammary gland, <2.5% of the administered radiocarbon was secreted in milk during the 72-h study period. The cumulative secretion of radioactive residues in milk of the cow treated by IU infusion represented 0.45% of the retained dose. Greater than 75% of this radioactivity was secreted in milk that was collected 12 h after dosing. During this period, the concentration of radioactivity was 9.3 ppb (NFZ equivalents); concentrations fell to 0.4 ppb by 72 h after treatment.
Radioactive residues secreted in milk after TO treatment followed a biphasic pattern during the 4-d treatment period. Milk secreted during the 12-h periods following treatment contained greater concentrations of radioactive residues than did milk secreted during the 12-to 24-h periods after treatment, which resulted in the accumulation of radioactive residues because milk secreted during the 12-h periods following the first, second, third, and fourth treatments contained increasingly greater concentrations of radioactive residues. These radioactive residues, however, were never >1 ppb of NFZ equivalents. Only 0.5% of the total administered radioactivity was secreted in milk after TO administration of [ 14 C]NFZ.
Excretion of radioactive residues in urine is shown in Table 3 . Urine contained 62.9, 43.7, and 17.5% of the administered radiocarbon for cows that received the IM, IU (effective dose), and TO treatments, respectively. The greatest amounts of radioactive residues were excreted in the urine during the 12-h periods immediately following dose administration. For example, 84.3 and 89.9% of the urinary radioactivity excreted after IM and IU administration of [ 14 C]NFZ was excreted during this 12-h period. Similarly, 72.5% of the urinary radioactivity from the cow that received the TO application was present in the urine collected during the four 12-h periods immediately following dosing.
Radioactive residues excreted in feces is shown in Table 4 . For the cow treated intramammarily with [ 14 C]NFZ, the greatest amount of radioactive residues excreted in feces was during the 12-to 24-h period after dosing. In contrast, approximately equal amounts of radioactive residues were excreted during the first and second 12-h periods postdosing in the cow that received the IU treatment. Fecal excretion of radioactive residues after repeated TO treatment with [ 14 C]NFZ did not follow a distinct pattern, except that radioactive residues in feces tended to decline during the withdrawal period. Table 5 shows radioactive residues present in tissues of the treated cows. Of the traditionally edible tissues (liver, kidney, skeletal muscle, and adipose tissue), livers and kidneys contained the greatest total residues, regardless of the route of administration. Of the traditionally nonedible tissues, the sites of [ 14 C]NFZ administration (mammary gland, uterus, and eyes) retained the highest concentrations of total residues. These tissues did not necessarily retain the largest percentage of the administered radioactivity.
Total recovery of radiocarbon for each of the cows is shown in Table 6 . Recovery was excellent for the cow treated intramammarily, but, for the cow that received the IU treatment, about 10% of the radioactivity was not recovered. This percentage of radioactivity was likely discharged from the vagina but was not recovered from the wood shavings or flooring material. The loss of approximately 30% of the administered radiocarbon from the cow that received the TO treatment probably occurred at slaughter when the head and hide were inadvertently allowed to get wet. Water that drained from the head and hide was not recovered. Even with this loss, radioactivity on the head and hide constituted 5.1 and 4.4% of the total administered radioactivity, respectively.
Parent NFZ in Milk
The distributions of radioactive materials in milk and the amount of parent NFZ present in milk from cows that received the IU and IM treatments is TABLE 5 . Total radioactive residues present in tissues after intramammary, intrauterine, or topical ocular application of [ 14 C]nitrofurazone to lactating Holstein cows. 1 Cow 1501 was administered a single dose of [ 14 C]nitrofurazone (65.6 mg; 2.916 mCi) by intramammary infusion. 2 Cow 1617 was administered a single dose of [ 14 C]nitrofurazone (131.2 mg; 2.636 mCi) by intrauterine infusion. However, 72.0% of the dose was discharged from the vagina (primarily between 0 and 6 h after dosing). Therefore, the percentage recovery was calculated on the effective dose (36.8 mg; 0.739 mCi). 3 Cow 1621 was administered [ 14 C]nitrofurazone (2.1 mg/d; 0.297 mCi/d) for 4 consecutive d. 4 Percentage of total radioactive dose administered (data from the intrauterine treatment is based on the effective dose). 5 Not applicable. 6 Data are from the dosed udder. 7 Not determined. 8 Data are from the undosed udders of the cow treated by intramammary infusion and are from the complete udders of the other cows. shown in Table 7 . The major portion of the radioactive material in milk remained in the aqueous fraction after acidification and extraction with ethyl acetate, suggesting that the major portion of radioactive material in milk was present as metabolites rather than parent NFZ. Most of the radioactive material present in the ethyl acetate fraction eluted with methanol after being placed on XAD-2. Of this material, however, only a minor portion was present as parent NFZ. Most of the radioactive material in the methanol extract was eluted from the reversephase HPLC column prior to parent NFZ. Control samples augmented with [ 14 C]NFZ were fractionated by the same method as was used for the treatment samples. In these samples, recovery of radioactive residues in the methanolic wash of the XAD-2 column was 86.3 ± 2.4%. These results suggest that the low recovery of NFZ from the treatment samples was not an artifact of the extraction method. The concentration of parent NFZ was only 1.2 ppb in milk samples obtained at 0 to 12 h from the cow that received the IU treatment (Table 7) . By 12 to 24 h, the concentration of parent NFZ had fallen to 0.3 ppb. Milk from the undosed quarters of the cow treated by IM infusion contained 0.3 and 0.1 ppb of parent NFZ at 0 to 12 and 12 to 24 h after dosing, respectively. Milk from the dosed quarter contained 11.4, 2.8, 0.7, and 0.3 ppb of NFZ at 0 to 12 h, 12 to 3 Undosed quarter. 4 Dosed quarter. 5 All values are expressed as percentages of the radiocarbon originally present in the respective milk samples. 6 Recovery of radioactivity = S (cream, aqueous layer, glassware residue, residue, nonretained, water eluent packing, polar fraction, nitrofurazone, and nonpolar fraction). 4 Percentage recovery = (summation of radioactive residues present in various fractions/radiocarbon dosed) × 100. 5 Not applicable. 6 Not determined. 
Route of dose administration
DISCUSSION
Even with the less than optimal recoveries of radiocarbon from two of the cows reported in this study, these data clearly indicate that radioactive material administered as [ 14 C]NFZ by either IM, IU, or TO application was absorbed into systemic circulation. Indeed, the cumulative excretion of radioactive residues in the milk of the cow dosed by the IM route was <2.5% of the total radioactivity administered, and the cumulative excretion of radiocarbon in urine was 62.9% of the total. These data indicate that NFZ and its metabolites, or both, readily enter systemic circulation and are widely distributed to edible and nonedible tissues in addition to being secreted in milk.
Although a minor route for excretion, radioactive residues were always present in milk, regardless of the route of [ 14 C]NFZ administration. Thus, the NFZ treatment of mammary, uterine, or ocular infections in lactating dairy cows would lead to illegal residues of NFZ in milk because there is no tolerance for NFZ or its metabolites in milk.
Parent NFZ was present at very low concentrations (<2 ppb) in the milk samples obtained from 0 to 12 h from the cow treated by IU administration and at 0 to 12 h and 12 to 24 h from the undosed quarters of the cow treated by IM administration. These results suggest that parent NFZ would not be a good marker compound to use when monitoring illegal NFZ use. Milk from the dosed quarter of the cow treated by IM infusion contained substantially more parent NFZ (11.4 ppb at 0 to 12 h after milking), but concentrations fell to <1 ppb within 24 h. For monitoring purposes, the concentrations of parent NFZ in commercial milk samples would likely be much too low for reliable detection using existing analytical methods.
Existing analytical techniques that are used to measure NFZ in biological matrices are not sensitive enough to detect the low concentrations of NFZ secreted in milk. For example, our attempts to measure the semicarbazide side chain of NFZ according to the method of Hoogenboom et al. ( 4 ) were largely unsuccessful. The method was developed for use in tissues of swine that received relatively large doses of NFZ. The limit of detection for the assay in milk in our study was about 25 ppb, a level that is not sensitive enough for the measurement of incurred residues generated in this study. Because metabolites of NFZ have not been identified ( 3 ) , they are not candidates for use as marker compounds.
Several analytical methods have been developed for NFZ in various matrices, but none are adequate to detect NFZ at the levels observed in this study. For example, Vilim and MacIntosh ( 1 0 ) developed an HPLC method to detect NFZ in milk; the limit of detection was reported to be 5 ppb, but recoveries were consistently <70%. Other more sensitive liquid chromatography methods have been developed (6, 8 ) for matrices other than those for milk. In general, these analytical methods were developed for situations in which the live animals received substantially greater doses of NFZ than the cows in this study. Because parent NFZ is a minor portion of the total radioactive residues in milk and because the total radioactive residues in milk are generally <10 ppb (even 12 h after dose administration), only a highly sensitive assay could detect NFZ in incurred samples. Quantification of NFZ residues in this study was possible only because radiolabeled NFZ was employed.
One analytical method that might have potential utility for the indirect detection of NFZ in milk at low levels was published by Ryan et al. ( 9 ) . That method is based on the acid extraction of NFZ residues followed by acid hydrolysis to 5-nitrofuraldehyde and analysis by gas chromatography. The limit of detection for NFZ in milk using this method was about 10 ppb, but a packed glass column was used. The use of a capillary gas chromatograph in the analysis of 5-nitrofuraldehyde in conjunction with a sensitive detection technique, such as selected ion monitoring, would likely reduce the detection limit substantially.
The limitation of such an assay is that it would not be specific for NFZ (i.e., NFZ metabolites or other 5-nitrofuran drugs might also be detected).
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